SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN)

SBI Securities Co. Ltd. acquired a new position in shares of Ocugen, Inc. (NASDAQ:OCGN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 49,942 shares of the company’s stock, valued at approximately $40,000.

Several other hedge funds also recently made changes to their positions in the company. MetLife Investment Management LLC grew its holdings in shares of Ocugen by 36.4% during the third quarter. MetLife Investment Management LLC now owns 89,508 shares of the company’s stock worth $89,000 after buying an additional 23,877 shares during the last quarter. Intech Investment Management LLC purchased a new position in shares of Ocugen during the third quarter worth about $93,000. SG Americas Securities LLC grew its holdings in shares of Ocugen by 72.7% during the fourth quarter. SG Americas Securities LLC now owns 152,176 shares of the company’s stock worth $123,000 after buying an additional 64,080 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Ocugen during the fourth quarter worth about $132,000. Finally, Franklin Resources Inc. purchased a new position in shares of Ocugen during the third quarter worth about $142,000. Hedge funds and other institutional investors own 10.27% of the company’s stock.

Ocugen Trading Down 1.8 %

Shares of OCGN stock opened at $0.55 on Wednesday. The business’s fifty day moving average price is $0.72 and its 200 day moving average price is $0.89. The firm has a market capitalization of $159.61 million, a PE ratio of -3.04 and a beta of 3.88. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.58 and a quick ratio of 2.58. Ocugen, Inc. has a 1-year low of $0.52 and a 1-year high of $2.11.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings results on Wednesday, March 5th. The company reported ($0.05) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.05). Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. The business had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same period in the prior year, the company posted ($0.03) EPS. As a group, sell-side analysts forecast that Ocugen, Inc. will post -0.2 EPS for the current fiscal year.

Analyst Ratings Changes

OCGN has been the topic of a number of research reports. Chardan Capital raised their price target on Ocugen from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of Ocugen in a report on Thursday, March 6th.

Ocugen Company Profile

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.